Welcome to our dedicated page for Geron news (Ticker: GERN), a resource for investors and traders seeking the latest updates and insights on Geron stock.
Geron Corporation reports recurring developments as a commercial-stage biopharmaceutical company focused on hematologic malignancies. Its first-in-class telomerase inhibitor RYTELO (imetelstat) is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes with transfusion-dependent anemia.
Company updates commonly cover RYTELO net product revenue, U.S. commercialization, financial results and guidance, and continued development of imetelstat in JAK-inhibitor relapsed or refractory myelofibrosis and other hematologic malignancies. Geron news also includes investor conference participation, Nasdaq inducement grants, board appointments, executive leadership changes, and restructuring-related business updates.
Geron Corporation (Nasdaq: GERN) will release its Q2 2021 financial results after market close on August 16, 2021. The results will be detailed in a press release available on the company’s website. Following this, a conference call will be held at 4:30 p.m. ET to discuss the results and recent events. Key highlights include ongoing Phase 3 clinical trials for imetelstat in hematologic malignancies. A live webcast will also be accessible on the company's site, with an archive available for 30 days.
Geron Corporation (Nasdaq: GERN) announced the grant of non-statutory stock options for 130,000 shares of its common stock to new employees, effective July 21, 2021. The exercise price is $1.33 per share, matching the closing price on the grant date. The options will vest over four years, with 12.5% vesting after six months and the remainder in equal monthly installments. This grant complies with Nasdaq Listing Rule 5635(c)(4) and follows the 2018 Inducement Award Plan. Geron focuses on developing imetelstat, a telomerase inhibitor, in hematologic diseases with ongoing Phase 3 trials.
Geron Corporation (Nasdaq: GERN) announced the publication of data from the IMbark Phase 2 trial in the Journal of Clinical Oncology, showcasing clinical benefits of imetelstat in treating relapsed or refractory myelofibrosis (MF). Key findings include improved symptom response rates and overall survival in patients with high disease burden. The upcoming IMpactMF Phase 3 trial will further assess imetelstat's efficacy against standard therapies, targeting 320 patients. Imetelstat, a first-in-class telomerase inhibitor, has received Fast Track designation from the FDA for MF and related conditions.
Geron Corporation (Nasdaq: GERN) announced new clinical data for imetelstat, a first-in-class telomerase inhibitor, presented at EHA2021 Virtual Congress. The data support imetelstat's mechanism targeting malignant stem and progenitor cells, emphasizing its potential to transform treatment for myelodysplastic syndromes (MDS) and myelofibrosis (MF). Results from the IMerge Phase 2 trial indicate durable transfusion independence, while safety analyses show manageable adverse events. Geron is conducting two Phase 3 trials for imetelstat, which has received Fast Track designation from the FDA.
Geron Corporation (Nasdaq: GERN) announced two poster presentations at the EHA Annual Congress regarding clinical data for imetelstat, a telomerase inhibitor. The posters, available on June 11, 2021, showcase findings from the Phase 2 IMbark and IMerge trials, highlighting imetelstat's efficacy in treating lower risk MDS and MF patients. Notably, it demonstrated clinical benefit across molecular subtypes and an acceptable safety profile. Geron is advancing imetelstat for regulatory approval, having received Fast Track designation from the FDA.
Geron Corporation (Nasdaq: GERN) reported financial results for Q1 2021, posting a net loss of $27.8 million, or $0.09 per share, compared to a loss of $16.4 million, or $0.08 per share, in Q1 2020. Revenues increased to $137,000 from $52,000 year-over-year. The company maintains $244.7 million in cash, expected to fund operations until 2022. Geron is progressing in two Phase 3 clinical trials for imetelstat, with 75% enrollment in MDS and the first patient dosed in MF. The company aims for a commercial launch of imetelstat in 2023, with ongoing preparations for regulatory filings.
Geron Corporation (Nasdaq: GERN) will release its first quarter 2021 financial results on May 10, 2021, after market close. A conference call will follow at 4:30 p.m. ET to discuss results and recent developments. Investors can access the press release and the live webcast on the company's website. Geron is advancing a first-in-class telomerase inhibitor, imetelstat, targeting hematologic malignancies and is currently conducting two Phase 3 trials: IMerge and IMpactMF. For further information, visit www.geron.com.
Geron Corporation (Nasdaq: GERN) announced the granting of non-statutory stock options for 220,000 shares to new employees as employment inducements. These options were issued on April 21, 2021, with an exercise price of $1.48, matching the closing stock price on the grant date. The options have a 10-year term and vest over four years, with an initial 12.5% vesting at the six-month mark. This action complies with Nasdaq Listing Rule 5635(c)(4). Geron is currently focused on developing its telomerase inhibitor, imetelstat, through two Phase 3 clinical trials.
Geron Corporation (Nasdaq: GERN) has initiated dosing for the first patient in its Phase 3 clinical trial, IMpactMF, studying imetelstat for refractory myelofibrosis (MF), with overall survival as the primary endpoint. This trial, targeting 320 patients, addresses a significant unmet need given the median overall survival of 14-16 months for those unresponsive to JAK inhibitors. Interim results are anticipated in 2024, with final results expected in 2025. Imetelstat is also Fast Track designated by the FDA for certain patient populations, enhancing its development prospects.
Geron Corporation (Nasdaq: GERN) announced the issuance of non-statutory stock options for 240,000 shares to newly hired employees. These options were granted on March 17, 2021, at an exercise price of $1.81 per share, matching the stock's closing price on that date. The options have a 10-year term and vest over four years, with 12.5% vesting after six months of employment. This grant complies with Nasdaq Listing Rule 5635(c)(4) and is part of Geron's 2018 Inducement Award Plan aimed at attracting new talent.